WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 269,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 70,000 shares of Arcutis’ common stock to 40 newly hired employees. These awards were approved by the Compensation Committee of Arc

-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial results for the quarter ended March 31, 2026 and provides a corporate up

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the first quarter ended March 31, 2026, before the market opens on Friday, May 15, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and pro

CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, o

Scientists have uncovered a hidden “stop-scratching” signal in the nervous system that tells your brain when enough scratching is enough. The discovery centers on a molecule called TRPV4, which acts like part of an internal braking system for itch relief. In experiments involving chronic itch similar to eczema, mice missing this signal scratched less often—but when they did scratch, they couldn’t stop.When an itch strikes, scratching usually brings relief after a few moments. Scientists have now

First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administration without lymphodepletion All non-human primates (6 of 6) exhibited deep B cell depletion in peripheral blood by Day 10 Potent B cell clearance observed across peripheral blood, lymph nodes and bone marrow Treatment was generally well tolerated, with no deaths, no neurotoxicity and no off-target CAR expression or integration detected in non-T cells

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares of Class A common stock and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Induc

Recommendations aim to help provide clearer safety information for use during pregnancy White Oak, Md., May 08, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a final guidance for industry, Postapproval Pregnancy Safety Studies , with recommendations on different methodologies that can be used in the postapproval setting to study the safety of drugs and biological products when used during pregnancy. Many pregnant women may benefit from medications to treat ongoi

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA) , a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026. After the meeting materials are finalized and filed with the Securities and Exchanges Commission, such materials will be mailed to shareholders. The Company also advises its Financial Statements included in its Annual Report

Scientists have uncovered a striking brain difference linked to psychopathy: people with psychopathic traits were found to have a striatum — a brain region tied to reward, motivation, and decision-making — that was about 10% larger on average than those without such traits. Using MRI scans and psychological assessments on 120 participants, researchers connected this enlarged brain region to thrill-seeking, impulsive behavior, and a stronger drive for stimulation.Neuroscientists have identified a